drugset / Trial / NCT02220972

To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures

NCT02220972

Phase 4 Withdrawn Eisai Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

This will be a multi-center, randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of 2007/Fycompa (perampanel) on sleep, in subjects with well controlled partial onset seizures (on an antiepileptic drug \[AED\] monotherapy) who are experiencing sleep onset insomnia.

Timeline

Start
2015-03
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 6 mg

Indications